| Lung Large Cell Neuroendocrine Carcinoma studied in …STUDIED_INderived15 of 15show fewer |
|---|
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07080242Phase 1 · recruiting Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors · condition mapped CURATED_BROADER · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07561645Phase 2 · not yet recruiting A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049966Phase 1 · completed Atezolizumab in Large Cell Neuroendocrine Carcinoma · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04010357Phase 2 · completed Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736418Phase 1 · active not recruiting Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05470595Phase 2 · active not recruiting A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510594Phase 2 · not yet recruiting A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05680922Phase 1 · active not recruiting DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393816Phase 2 · recruiting FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06418087Phase 2 · recruiting Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901378Phase 2 · withdrawn Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02755675Phase 2 · unknown uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02943798Phase 2 · unknown Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma · condition mapped ALIAS · 15 trials mapped (10 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |